Royal Bank of Canada Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT - Get Free Report) had its price target lowered by equities research analysts at Royal Bank of Canada from $9.00 to $7.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a "sector perform" rating on the stock. Royal Bank of Canada's price target would indicate a potential upside of 27.27% from the stock's current price.

A number of other research firms have also recently weighed in on HCAT. Stephens increased their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a report on Thursday, November 14th. Citigroup dropped their price target on shares of Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. Evercore ISI lifted their price target on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a report on Tuesday, October 8th. Piper Sandler reissued an "overweight" rating and issued a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $11.27.

Health Catalyst Stock Performance

HCAT stock traded down $0.26 during midday trading on Wednesday, reaching $5.50. The company had a trading volume of 1,157,402 shares, compared to its average volume of 776,470. The firm has a market capitalization of $334.68 million, a PE ratio of -4.07 and a beta of 1.36. The stock has a 50 day moving average price of $7.68 and a 200 day moving average price of $7.53. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $10.99. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The company's revenue for the quarter was up 3.5% compared to the same quarter last year. Analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current year.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, Director Duncan Gallagher sold 4,500 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $6.93, for a total value of $31,185.00. Following the sale, the director now directly owns 69,938 shares in the company, valued at approximately $484,670.34. The trade was a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel Lesueur sold 5,209 shares of the company's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total transaction of $40,109.30. Following the completion of the sale, the chief operating officer now directly owns 129,690 shares of the company's stock, valued at $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 74,727 shares of company stock valued at $601,810. 2.50% of the stock is owned by corporate insiders.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC boosted its holdings in Health Catalyst by 438.5% during the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company's stock worth $25,279,000 after buying an additional 3,221,408 shares in the last quarter. Millennium Management LLC lifted its position in shares of Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company's stock valued at $15,421,000 after acquiring an additional 1,184,131 shares during the last quarter. Nepsis Inc. boosted its stake in shares of Health Catalyst by 67.9% during the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company's stock worth $17,131,000 after acquiring an additional 851,448 shares in the last quarter. Fred Alger Management LLC acquired a new position in shares of Health Catalyst in the 3rd quarter worth $6,858,000. Finally, Portolan Capital Management LLC acquired a new position in shares of Health Catalyst in the 3rd quarter worth $5,402,000. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.